Novel Imaging Techniques for Neuroendocrine Tumors

Phase 1

Recruiting

Led By Steve Cho, MD

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 96 hours post-dose

Awards & highlights

No Placebo-Only Group

Summary

This trial seeks to find out if PET/CT scans can improve safety of a cancer treatment for neuroendocrine tumors. Participants will have 6 visits for scans.

Who is the study for?

This trial is for people with neuroendocrine tumors who are candidates for a treatment called Lutathera. Participants should be able to lie flat and tolerate PET/CT or SPECT/CT scans without known incompatibilities, and must be likely to follow study procedures.

What is being tested?

The study tests if DetectnetTM PET/CT can make Lutathera therapy safer. It involves two phases with six visits where participants undergo additional research PET/CT, and possibly SPECT/CT scans.

What are the potential side effects?

Potential side effects may include discomfort from lying still during scans, reactions to contrast agents used in imaging (like itching or rash), radiation exposure risks, and anxiety from being in enclosed spaces during the scan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a candidate for a specific treatment targeting my neuroendocrine tumor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 96 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 96 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour post-dose, 4 hours post-dose, 48 hours post-dose, 96 hours post-dose for reporting.